# Alnylam Pharmaceuticals, Inc. – Consensus ‘buy’ rating and 28.6% Upside Potential

- Link: https://www.directorstalkinterviews.com/alnylam-pharmaceuticals-inc.consensus-buy-rating-and-28.6-upside-potential/4121126298
- Published: 2023-08-30T11:10:53+01:00
- Author: Charlotte Edwards

**Alnylam Pharmaceuticals, Inc.** with ticker code (ALNY) now have 23 confirmed 
analysts covering the stock with the consensus suggesting a rating of ‘buy’. The
range between the high target price and low target price is between 405 and 141 
suggesting an average Analsyt target price of $246.47. Now with the previous closing
price of $191.66 this is indicating there is a potential upside of 28.6%. The 50
day MA is $192.80 and the 200 moving average now moves to $205.40. The total market
capitalization for the company now stands at 24.31B. The stock price for the company
is currently is currently 194.46 USD

 The potential market cap would be $31,259,092,865 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of 10.01 and
a -15.34% return on assets.

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The
Company is engaged in developing therapeutics based on ribonucleic acid interference(
RNAi). Its pipeline includes five marketed products and over ten clinical programs,
including several in late-stage development, across four strategic therapeutic areas(
STArs): genetic medicines, cardio-metabolic diseases, hepatic infectious diseases,
and CNS/ocular diseases. Its RNAi-based medicines include ONPATTRO (patisiran), 
AMVUTTRA (vutrisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran).
ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin
amyloidosis. GIVLAARI is used to reduce induced liver aminolevulinic acid synthase
1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease
manifestations of acute hepatic porphyria. OXLUMO is an RNAi therapeutic targeting
hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1.

Share on: